Gliomas, being among the most common types of CNS tumors, have distinct clinical outcomes and treatment strategies based on different tumor grades, isocitrate dehydrogenase (IDH) mutation, and 1p/19q codeletion statuses. The gene discussed is IDH3A; the disease is central nervous system cancer.